Quick Takeaways
- Barbara Gayle Duncan has 6 issuer positions tracked on this page.
- Estimated disclosed ownership value: $1,479,011.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Barbara Gayle Duncan
- Location
- Boston, MA
- Summary
- The estimated net worth of Barbara Gayle Duncan is at least $1,479,011 dollars as of 02 Mar 2026. Barbara Gayle Duncan is the Director of HALOZYME THERAPEUTICS, INC. and owns shares of HALOZYME THERAPEUTICS, INC. (HALO) stock worth about $1.2M. Barbara Gayle Duncan is the Director of Atea Pharmaceuticals, Inc. and owns shares of Atea Pharmaceuticals, Inc. (AVIR) stock worth about $279.5K.
- Signature
- /s/ Jeffrey Rona, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Barbara Gayle Duncan and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: HALOZYME THERAPEUTICS, INC. ($1,199,522).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Barbara Gayle Duncan
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| HALO | HALOZYME THERAPEUTICS, INC. | Director | $1,199,522 | 01 May 2025 | ||
| AVIR | Atea Pharmaceuticals, Inc. | Director | $279,489 | 20 Jun 2025 | ||
| ADAP | Adaptimmune Therapeutics PLC | Director | 01 Jul 2022 | |||
| FUSN | Fusion Pharmaceuticals Inc. | Director | 04 Jun 2024 | |||
| JNCE | Jounce Therapeutics, Inc. | Director | 03 May 2023 | |||
| OVID | Ovid Therapeutics Inc. | Director | 26 Feb 2026 |
Insider Transactions Reported by Barbara Gayle Duncan:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.